Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial

Abstract Background Opioid use disorder (OUD) is a devastating condition with frequent suicidality, contributing to overdose deaths. Theta burst stimulation (TBS) to the dorsolateral prefrontal cortex (DLPFC) is used to treat major depressive disorder (MDD) and is effective in treating suicidal id...

Full description

Saved in:
Bibliographic Details
Main Authors: Victor M. Tang, Bernard Le Foll, Zafiris J. Daskalakis, An-Li Wang, Leslie Buckley, Daniel M. Blumberger, Daphne Voineskos
Format: Article
Language:English
Published: Cambridge University Press 2025-01-01
Series:European Psychiatry
Subjects:
Online Access:https://www.cambridge.org/core/product/identifier/S0924933825000288/type/journal_article
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849333669499502592
author Victor M. Tang
Bernard Le Foll
Zafiris J. Daskalakis
An-Li Wang
Leslie Buckley
Daniel M. Blumberger
Daphne Voineskos
author_facet Victor M. Tang
Bernard Le Foll
Zafiris J. Daskalakis
An-Li Wang
Leslie Buckley
Daniel M. Blumberger
Daphne Voineskos
author_sort Victor M. Tang
collection DOAJ
description Abstract Background Opioid use disorder (OUD) is a devastating condition with frequent suicidality, contributing to overdose deaths. Theta burst stimulation (TBS) to the dorsolateral prefrontal cortex (DLPFC) is used to treat major depressive disorder (MDD) and is effective in treating suicidal ideation. We piloted a randomized, double-blind, sham-controlled trial of bilateral rTMS for patients with OUD and MDD experiencing suicidality. Methods Sequential bilateral TBS was delivered guided by structural neuroimaging: continuous TBS to the right then intermittent TBS to the left DLPFC, daily (20 treatments). The primary objective was to determine the feasibility of this population. The primary clinical outcome was the scale for suicidal ideation (SSI), secondary outcomes included depressive symptoms and opioid cue-induced craving. ClinicalTrials.gov: NCT04785456. Results Eighty-seven individuals were pre-screened. The most common reasons for ineligibility included being unreachable by the study team, difficulty with scheduling/travel requirements, and medical/psychiatric instability. Six participants (5:1 M:F) were enrolled (3/arm), four had a fentanyl use history; two completed per protocol (1/arm). Of the participants with follow-up data, SSI scores decreased in 2/3 in the sham arm and 2/2 in the active arm; depression and opioid craving scores decreased in all participants. Conclusion We present the first data piloting a structural neuroimaging-guided, multi-session rTMS treatment course in outpatients with suicidality and OUD in the current North American context. Recruitment and retention were the main challenges given the highly unstable medical and psychosocial context of this patient population. Future trials should consider a suitable environment to improve the feasibility of delivering this treatment.
format Article
id doaj-art-06ebcbbc0ad94537a062bc390fc722d6
institution Kabale University
issn 0924-9338
1778-3585
language English
publishDate 2025-01-01
publisher Cambridge University Press
record_format Article
series European Psychiatry
spelling doaj-art-06ebcbbc0ad94537a062bc390fc722d62025-08-20T03:45:47ZengCambridge University PressEuropean Psychiatry0924-93381778-35852025-01-016810.1192/j.eurpsy.2025.28Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trialVictor M. Tang0https://orcid.org/0000-0001-5365-9683Bernard Le Foll1https://orcid.org/0000-0002-6406-4973Zafiris J. Daskalakis2An-Li Wang3Leslie Buckley4https://orcid.org/0000-0002-3134-7504Daniel M. Blumberger5https://orcid.org/0000-0002-8422-5818Daphne Voineskos6https://orcid.org/0000-0002-7450-4434Institute of Medical Science, University of Toronto, Toronto, ON, Canada Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, CanadaInstitute of Medical Science, University of Toronto, Toronto, ON, Canada Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada Institute for Mental Health Policy Research, Centre for Addiction and Mental Health, Toronto, ON, Canada Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, Canada Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada Waypoint Research Institute, Waypoint Centre for Mental Health Care, Penetanguishene, ON CanadaDepartment of Psychiatry, University of California, San Diego, CA, USAIcahn School of Medicine at Mount Sinai, New York, NY, USADepartment of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada Addictions Division, Centre for Addiction and Mental Health, Toronto, ON, CanadaInstitute of Medical Science, University of Toronto, Toronto, ON, Canada Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, CanadaInstitute of Medical Science, University of Toronto, Toronto, ON, Canada Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, ON, Canada Poul Hansen Family Centre for Depression, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, ON, Canada Abstract Background Opioid use disorder (OUD) is a devastating condition with frequent suicidality, contributing to overdose deaths. Theta burst stimulation (TBS) to the dorsolateral prefrontal cortex (DLPFC) is used to treat major depressive disorder (MDD) and is effective in treating suicidal ideation. We piloted a randomized, double-blind, sham-controlled trial of bilateral rTMS for patients with OUD and MDD experiencing suicidality. Methods Sequential bilateral TBS was delivered guided by structural neuroimaging: continuous TBS to the right then intermittent TBS to the left DLPFC, daily (20 treatments). The primary objective was to determine the feasibility of this population. The primary clinical outcome was the scale for suicidal ideation (SSI), secondary outcomes included depressive symptoms and opioid cue-induced craving. ClinicalTrials.gov: NCT04785456. Results Eighty-seven individuals were pre-screened. The most common reasons for ineligibility included being unreachable by the study team, difficulty with scheduling/travel requirements, and medical/psychiatric instability. Six participants (5:1 M:F) were enrolled (3/arm), four had a fentanyl use history; two completed per protocol (1/arm). Of the participants with follow-up data, SSI scores decreased in 2/3 in the sham arm and 2/2 in the active arm; depression and opioid craving scores decreased in all participants. Conclusion We present the first data piloting a structural neuroimaging-guided, multi-session rTMS treatment course in outpatients with suicidality and OUD in the current North American context. Recruitment and retention were the main challenges given the highly unstable medical and psychosocial context of this patient population. Future trials should consider a suitable environment to improve the feasibility of delivering this treatment. https://www.cambridge.org/core/product/identifier/S0924933825000288/type/journal_articlemajor depressive disorderopioid use disordersuicidetheta burst stimulationtranscranial magnetic stimulation
spellingShingle Victor M. Tang
Bernard Le Foll
Zafiris J. Daskalakis
An-Li Wang
Leslie Buckley
Daniel M. Blumberger
Daphne Voineskos
Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
European Psychiatry
major depressive disorder
opioid use disorder
suicide
theta burst stimulation
transcranial magnetic stimulation
title Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
title_full Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
title_fullStr Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
title_full_unstemmed Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
title_short Repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder: a pilot feasibility randomized controlled trial
title_sort repetitive transcranial magnetic stimulation for the treatment of suicidality in opioid use disorder a pilot feasibility randomized controlled trial
topic major depressive disorder
opioid use disorder
suicide
theta burst stimulation
transcranial magnetic stimulation
url https://www.cambridge.org/core/product/identifier/S0924933825000288/type/journal_article
work_keys_str_mv AT victormtang repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT bernardlefoll repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT zafirisjdaskalakis repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT anliwang repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT lesliebuckley repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT danielmblumberger repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial
AT daphnevoineskos repetitivetranscranialmagneticstimulationforthetreatmentofsuicidalityinopioidusedisorderapilotfeasibilityrandomizedcontrolledtrial